Ambrx vs BeiGene
Ambrx vs BeiGene, compared side by side on 15 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: Ambrx is on 35/100 and BeiGene on 64/100.
Where each one leads
Ambrx
- funding raised: $462M against $358M
BeiGene
- our overall score: 64/100 against 35/100
- agent readiness: 50/100 against 22/100
- domain rating: 68/100 against 36/100
At a glance
| Measure | Ambrx | BeiGene |
|---|---|---|
| What it is | Clinical-stage biopharmaceutical company developing next-generation antibody-drug conjugates (ADCs) for cancer treatment. | A global oncology company developing and commercializing innovative cancer treatments. |
| Category | Biotechnology, Drug Discovery, Oncology, Antibody-Drug Conjugates (ADCs) | Biotech, MedTech, HealthTech, Genomics |
| Sells toBusiness model | B2B | B2B |
| Offering | Software | hardware | services | marketplace | platform | Platform |
| Founded | 2003 | 2010 |
| Headquarters | San Diego, United States | Cambridge, United States |
| Status | Inactive | Active |
Size, funding and growth
| Measure | Ambrx | BeiGene |
|---|---|---|
| Open roles | Not published | 100 |
| Total funding | $462M | $358M |
| Latest round | ATM | Secondary Offering |
| Valuation | Not published | $15B |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | Ambrx | BeiGene |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 35/100 | 64/100 |
| Traction | 40/100 | 40/100 |
| Team | 70/100 | 30/100 |
| Community | 12/100 | Not published |
| Search visibility | Not published | 17/100 |
| Quality | 30/100 | 88/100 |
| Agent readinessHow well an AI agent can read and act on the site | F (22/100) | D (50/100) |
| Domain ratingLink authority, 0-100 | 36/100 | 68/100 |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | Ambrx | BeiGene |
|---|---|---|
| CDN | Not detected | Cloudflare |
| CMS | Not detected | WordPress |
| Frameworks | Not detected | Jquery, Tailwind CSS, Bootstrap |
Ambrx vs BeiGene: common questions
Which is better, Ambrx or BeiGene?
On our 0-100 score BeiGene rates higher (64/100 against 35/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 15 data points above: read the rows that match what you are buying for.
How do Ambrx and BeiGene compare on the numbers?
Ambrx leads on funding raised ($462M against $358M). BeiGene leads on our overall score (64/100 against 35/100), agent readiness (50/100 against 22/100), domain rating (68/100 against 36/100).
Read the full Ambrx review and pricing or the BeiGene review and pricing. You can also browse other Ambrx alternatives we track.